Indolent Lymphoma
Feature
CLL drug in limited supply outside U.S.
Patients outside the United States will be able to access the drug only through compassionate use programs.
Conference Coverage
AUDIO: Immunotherapy’s role in NHL
Dr. Stephen Ansell outlines the challenges in using immunotherapy effectively in non-Hodgkin lymphoma and future directions.
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
From the Journals
Pemphigus associated with higher risk of hematologic malignancies
Patients with pemphigus were twice as likely to have chronic leukemia and multiple myeloma.
Conference Coverage
Study identifies predictors of acquired von Willebrand disease
ATLANTA – Successfully treating Waldenström macroglobulinemia often resolves acquired von Willebrand disease.
From the Journals
Rare neurological complication linked to Waldenstrom disease
A 67-year-old man with Waldenstrom disease experienced bilateral facial nerve palsy.
From the Journals
Rituximab may be best choice for splenic MZL
Rituximab monotherapy appears to outperform splenectomy based on retrospective data.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
From the Journals
Novel therapies may expand anti-MZL toolbox
Treatment successes in other hematologic malignancies offer promise for MZL.
From the Journals
Rare epidermotropic MZL yields to rituximab
A case of epidermotropic MZL in an otherwise healthy 69-year-old man shows the efficacy of rituximab.
From the Journals
Upfront chemotherapy yields excellent survival in patients with MZLs
The study assessed FND-R or CHOP-R as upfront chemotherapy regimens in patients with either extranodal, nodal, or splenic MZL.